Informations: Ceci n’est pas la version la plus récente du modèle de données. Vous trouverez un aperçu de la version à gauche, sous Versions. Vous trouverez la version la plus actuelle ici.
Informations:
Erreur:
ID
12210
Description
Post Marketing Surveillance (PMS) Study of Ryzodeg™ (Insulin Degludec /Insulin Aspart) in Patients With Diabetes Mellitus in Routine Clinical Practice in India; ODM derived from: https://clinicaltrials.gov/show/NCT02230618
Lien
https://clinicaltrials.gov/show/NCT02230618
Mots-clés
Versions (2)
- 18/10/2015 18/10/2015 -
- 19/10/2015 19/10/2015 - Julian Varghese
Téléchargé le
18 octobre 2015
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY-NC 3.0 Legacy
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Eligibility Diabetes NCT02230618
Eligibility Diabetes NCT02230618
- StudyEvent: Eligibility
Similar models
Eligibility Diabetes NCT02230618
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
informed consent
Item
informed consent obtained before any study-related activities. (study-related activities are any procedures that are related to recording of data according to the protocol). the historical data including the data before informed consent obtained (e.g., hba1c (glycated haemoglobin ), fpg (fasting plasma glucose), pppg (postprandial plasma glucose), severe hypoglycaemia before the start of ryzodeg therapy) can be used for baseline data
boolean
C0021430 (UMLS CUI [1])
Diabetes Mellitus, Insulin-Dependent; ryzodeg
Item
patients with insulin requiring diabetes mellitus and who are scheduled to start treatment with ryzodeg™ based on the clinical judgment of their treating physician
boolean
C0011854 (UMLS CUI [1])
C3661220 (UMLS CUI [2])
C3661220 (UMLS CUI [2])
allergy; ryzodeg
Item
known or suspected allergy to ryzodeg™ any of the active substances or any of the excipients
boolean
C0020517 (UMLS CUI [1])
C3661220 (UMLS CUI [2])
C3661220 (UMLS CUI [2])
participation
Item
previous participation in this study
boolean
C0679823 (UMLS CUI [1])
Clinical Research; Disruption
Item
mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
boolean
C0008972 (UMLS CUI [1])
C0332453 (UMLS CUI [2])
C0332453 (UMLS CUI [2])
therapy; ryzodeg
Item
patients who are or have previously been on ryzodeg™ therapy
boolean
C0087111 (UMLS CUI [1])
C3661220 (UMLS CUI [2])
C3661220 (UMLS CUI [2])
clinical trials other
Item
patients who are participating in other studies or clinical trials
boolean
C0008976 (UMLS CUI [1,1])
C0205394 (UMLS CUI [1,2])
C0205394 (UMLS CUI [1,2])
pregnant; breast feeding
Item
patients who are pregnant, breast feeding or have the intention of becoming pregnant within the following 12 months
boolean
C0549206 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0006147 (UMLS CUI [2])